



# TITAN BIOTECH LTD.

AN ISO 9001:2015 CERTIFIED COMPANY



Office : 903-909, 9<sup>th</sup> Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India  
Tel. : 011-27355742, 71239900 (44 Lines) | Fax : +91-11-47619811 | CIN: L74999RJ1992PLC013387

To,

10.08.2023

Corporate Services Department,  
BSE Ltd.,  
Phiroze Jeejeebhoy Tower,  
Dalal Street,  
Mumbai- 400001

Dear Sir,

## **Sub: Outcome Of Board Meeting**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors, at its meeting held today i.e. **Thursday, 10<sup>th</sup> August, 2023**, at the office of company, have inter-alia-

1. Approved the Standalone and Consolidated Unaudited Financial Results and Limited Review Report for the quarter ended 30<sup>th</sup> June, 2023.

In terms of the Provisions of Regulation 33 and of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the following:

1. Unaudited Financial Results for the quarter ended 30<sup>th</sup> June, 2023.
2. Limited Review Report for the quarter ended 30<sup>th</sup> June, 2023.

The meeting of Board of Directors commenced at 03:00 P.M. and concluded at 03:30 P.M.

The above information will be available on the website of the company i.e <https://titanbiotechltd.com>

This is for your kind information and record please.

**Thanking You.**

**Yours faithfully,**

**For Titan Biotech Ltd**

**Charanjit Singh**

**Company Secretary & Compliance Officer**

**M.No A12726**

Encl: As above

**R.O. & Works:** Unit I: A-902 A, RIICO Industrial Area, Phase-III, Bhiwadi-301019, Rajasthan  
Unit II: E-540, Industrial Area, Chopanki, Bhiwadi-301019, Rajasthan

**E-mail:** [marketing@titanbiotechltd.com](mailto:marketing@titanbiotechltd.com)

**Website:** [www.titanbiotechltd.com](http://www.titanbiotechltd.com) | [www.titanmedia.in](http://www.titanmedia.in)



# **A N S K & Associates**

**CHARTERED ACCOUNTANTS**

**OFFICE : 414, RG Trade Tower, Netaji Subhash Place,  
Pitampura, Delhi-110034**

**OFFICE NO. 011-46010089**

**EMAIL :amccorporateservices@gmail.com**

---

---

## **Independent Auditor's Review Report on Quarterly and year to date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

To,

THE BOARD OF DIRECTORS  
TITAN BIOTECH LIMITED

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Titan Biotech Limited ('the Company') for the quarter ended 30 June 2023, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



# A N S K & Associates

CHARTERED ACCOUNTANTS

OFFICE : 414, RG Trade Tower, Netaji Subhash Place,

Pitampura, Delhi-110034

OFFICE NO. 011-46010089

EMAIL :amccorporateservices@gmail.com

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

## For A N S K & Associates

Chartered Accountants

Firm's Registration No. 026177N

(CA Akhil Mittal)  
Partner

M.No. 517856

Date: 10.08.2023

Place: New Delhi

UDIN: **23517856BGUXFV4273**

AKHIL  
MITTAL

Digitally signed by AKHIL  
MITTAL  
DN: cn=AKHIL MITTAL, o, ou,  
email=amccorporateservices  
@gmail.com, c=US  
Date: 2023.08.10 13:44:39  
+05'30'



# A N S K & Associates

CHARTERED ACCOUNTANTS

OFFICE : 414, RG Trade Tower, Netaji Subhash Place,  
Pitampura, Delhi-110034

OFFICE NO. 011-46010089

EMAIL :amccorporateservices@gmail.com

---

---

## **Independent Auditor's Review Report on Quarterly and Year to date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

To,

THE BOARD OF DIRECTORS  
TITAN BIOTECH LIMITED

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Titan Biotech Limited ('the Holding Company') and its associate for the quarter ended 30 June 2023, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 193 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



# A N S K & Associates

CHARTERED ACCOUNTANTS

OFFICE : 414, RG Trade Tower, Netaji Subhash Place,  
Pitampura, Delhi-110034

OFFICE NO. 011-46010089

EMAIL :amccorporateservices@gmail.com

- 
4. The Statement includes results of the Holding Company -Titan Biotech Limited and Associate Company - Peptech Biosciences Limited.
  5. The accompanying unaudited consolidated financial results include unaudited interim financial results and other unaudited financial information in respect of its associates which have been approved and furnished to us by the management. Our Conclusion on the statement is not modified in respect of the above matter.
  6. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
  7. The unaudited consolidated financial results also includes the Group's share of net profit after tax of Rs.75.12 lacs and total comprehensive income of Rs.75.12 Lacs for the quarter ended 30th June 2023, as considered in the consolidated unaudited financial results, in respect of its Associates, based on their interim financial results of M/s Peptech biosciences Limited which have been reviewed by our Audit Firm. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of its associates, are based solely on such unaudited interim financial results. According to the information and explanations given to us by the management, these interim financial results are not material to the Group.

Our conclusion is not modified in respect of this matter.

## For A N S K & Associates

Chartered Accountants

Firm's Registration No. 026177N

(CA Akhil Mittal)

Partner

M.No. 517856

Date: 10.08.2023

Place: New Delhi

UDIN: **23517856BGUXFW2579**

**AKHIL  
MITTAL**

Digitally signed by AKHIL  
MITTAL  
DN: cn=AKHIL MITTAL, o, ou,  
email=amccorporateservices  
@gmail.com, c=US  
Date: 2023.08.10 13:43:59  
+05'30'



**TITAN BIOTECH LIMITED**

Regd. Office :- A-902 A, RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2023**

(Rs. IN LAKHS) except for EPS


| Sr. No | PARTICULARS   | STANDALONE      |                 |                 |                  |
|--------|---|-----------------|-----------------|-----------------|------------------|
|        |   | QUARTER ENDED   |                 | YEAR ENDED      |                  |
|        |   | 30.06.2023      | 31.03.2023      | 30.06.2022      | 31.03.2023       |
|        |   | UNAUDITED       | AUDITED         | UNAUDITED       | AUDITED          |
| 1      | <b>INCOME</b>   |                 |                 |                 |                  |
|        | Revenue from operations   | 3,474.74        | 3,683.63        | 3,499.62        | 14,399.93        |
|        | Other Income  | 28.19           | 49.20           | 31.64           | 194.33           |
|        | <b>Total Income</b>   | <b>3,502.93</b> | <b>3,732.83</b> | <b>3,531.26</b> | <b>14,594.26</b> |
| 2      | <b>EXPENSES</b>   |                 |                 |                 |                  |
|        | Cost of Materials Consumed  | 1,891.56        | 1,728.01        | 1,784.39        | 7,080.54         |
|        | Changes in inventories of Finished Goods, Stock-in-Trade and Work-in-Progress | (434.96)        | 8.85            | (60.73)         | (93.21)          |
|        | Employee Benefit Expenses   | 541.77          | 522.08          | 379.95          | 1,820.90         |
|        | Finance Costs   | 28.56           | 25.71           | 17.59           | 74.59            |
|        | Depreciation and Amortization Expenses  | 79.60           | 71.08           | 60.45           | 260.03           |
|        | Other Expenses  | 687.63          | 741.48          | 589.37          | 2,639.80         |
|        | <b>Total Expenses</b>   | <b>2,794.16</b> | <b>3,097.21</b> | <b>2,771.02</b> | <b>11,782.65</b> |
| 3      | Profit/(loss) before exceptional items and tax (1-2)                          | 708.77          | 635.62          | 760.24          | 2,811.61         |
| 4      | Exceptional Items   |                 |                 |                 |                  |
| 5      | Profit/ (loss) before tax (3+4)   | 708.77          | 635.62          | 760.24          | 2,811.61         |
| 6      | Tax expense:  |                 |                 |                 |                  |
|        | (I) Current Tax   | 167.40          | 177.93          | 181.86          | 721.44           |
|        | (II) Deferred Tax   | 0.74            | (6.67)          | 0.65            | (8.89)           |
|        | (III) Earlier year taxes  | (0.31)          | -               | -               | (3.43)           |
|        | <b>Total Tax (I+II)</b>   | <b>167.83</b>   | <b>171.26</b>   | <b>182.51</b>   | <b>709.12</b>    |
| 7      | Profit (Loss) for the period after Tax (5-6)                                  | 540.94          | 464.36          | 577.73          | 2,102.49         |
| 8      | <b>Other comprehensive income (Net of Tax)</b>                                |                 |                 |                 |                  |
| A.     | Items that will not be reclassified to profit or loss                         |                 |                 |                 |                  |
|        | Re-measurement gain on defined benefit plans                                  | 1.55            | 6.22            | -               | 6.22             |
| B      | (i) Items that will be reclassified to profit or loss                         |                 |                 |                 |                  |
|        | (ii) Income tax relating to items that will be reclassified to profit or loss |                 |                 |                 |                  |
|        | <b>Total Other Comprehensive Income for the period (A+B)(net of taxes)</b>    | <b>1.55</b>     | <b>6.22</b>     | <b>-</b>        | <b>6.22</b>      |
| 9      | <b>Total Comprehensive Income for the period (7+8)</b>                        | <b>542.49</b>   | <b>470.58</b>   | <b>577.73</b>   | <b>2,108.71</b>  |
| 10     | Paid-up equity share capital (Face Value of Rs. 10/- each)                    | 826.37          | 826.37          | 826.37          | 826.37           |
| 11     | Other Equity  |                 |                 | -               | 9,782.79         |
| 12     | Earnings per equity share (face value of Rs.10/- each) not annualised         |                 |                 |                 |                  |
|        | (1) Basic   | 6.55            | 5.62            | 6.99            | 25.44            |
|        | (2) Diluted   | 6.55            | 5.62            | 6.99            | 25.44            |

**Notes:**

- The above unaudited standalone financial results for the quarter ended on 30.06.2023 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on August 10, 2023. The Statutory Auditors of the Company have carried out a limited review in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements), 2015. The results for the quarter ended June 30, 2023, are available on the BSE Limited website(www.bseindia.com) and on the company's Website(www.titanbiotechltd.com)
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter ended on 30th June 2023 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The standalone unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operation for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors  
for TITAN BIOTECH LIMITED

*Naresh Kumar Singla*  
NARESH KUMAR SINGLA  
Managing Director  
DIN-00027448



Place : Delhi  
Dated : 10.08.2023

**TITAN BIOTECH LIMITED**

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Fax No. +91-11-47619811 Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2023**

(Rs. IN LAKHS) except for EPS

| Sr. No. | PARTICULARS  | STANDALONE    |            |            |            |
|---------|--|---------------|------------|------------|------------|
|         |  | QUARTER ENDED |            | YEAR ENDED |            |
|         |  | 30.06.2023    | 31.03.2023 | 30.06.2022 | 31.03.2023 |
|         |  | UNAUDITED     | AUDITED    | UNAUDITED  | AUDITED    |
| 1       | Total Income from Operations (Net)   | 3,502.93      | 3,732.83   | 3,531.26   | 14,594.26  |
| 2       | Net Profit/(Loss) for the period (before tax, exceptional and/or extraordinary items)  | 708.77        | 635.62     | 760.24     | 2,811.61   |
| 3       | Net Profit/(Loss) for the period before tax (after exceptional and/or extraordinary items)   | 708.77        | 635.62     | 760.24     | 2,811.61   |
| 4       | Net Profit/(Loss) for the period after tax (after exceptional and/or extraordinary items)  | 540.94        | 464.36     | 577.73     | 2,102.49   |
| 5       | Total comprehensive income for the period (comprising Profit/(Loss) for the period (after tax) and Other Comprehensive income (after tax) (refer note 3) | 542.49        | 470.58     | 577.73     | 2,108.71   |
| 6       | Paid-up Equity Share Capital ( Face value of Rs. 10/- per share)   | 826.37        | 826.37     | 826.37     | 826.37     |
| 7       | Other Equity excluding Revaluation Reserves as per the balance sheet   | -             | -          | -          | 9,782.79   |
| 8       | Earning Per Share (of INR 10/- each)   |               |            |            |            |
|         | (a) Basic  | 6.55          | 5.62       | 6.99       | 25.44      |
|         | (b) Diluted  | 6.55          | 5.62       | 6.99       | 25.44      |

**NOTES :**

- The above is an extract of the detailed format of standalone unaudited Financial Results for the quarter ended on 30.06.2023 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone unaudited Financial Results for the said quarter ended on 30.06.2023 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com. The statutory auditors of the company have carried out a limited review of the aforesaid results.
- The above unaudited standalone financial results for the quarter ended on 30.06.2023 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on August 10, 2023. The Statutory Auditors of the Company have carried out a limited review in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements), 2015. The results for the quarter ended June 30, 2023, are available on the BSE Limited website (www.bseindia.com) and on the company's Website (www.titanbiotechltd.com).
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law (Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter ended on 30.06.2023 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The standalone unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operation for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors  
for TITAN BIOTECH LIMITED

  
NARESH KUMAR SINGLA  
Managing Director  
DIN-00027448



Place : Delhi  
Dated : 10.08.2023



**TITAN BIOTECH LIMITED**

Regd. Office :- A-902 A, RILCO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

**STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2023**

(Rs. IN LAKHS) except for EPS

| Sr. No | PARTICULARS   | CONSOLIDATED    |                 |                 |                  |
|--------|---|-----------------|-----------------|-----------------|------------------|
|        |   | QUARTER ENDED   |                 | YEAR ENDED      |                  |
|        |   | 30.06.2023      | 31.03.2023      | 30.06.2022      | 31.03.2023       |
|        |   | UNAUDITED       | AUDITED         | UNAUDITED       | AUDITED          |
| 1      | <b>INCOME</b>   |                 |                 |                 |                  |
|        | Revenue from operations   | 3,474.74        | 3,683.63        | 3,499.62        | 14,399.93        |
|        | Other Income  | 28.19           | 49.20           | 31.64           | 194.33           |
|        | <b>Total Income</b>   | <b>3,502.93</b> | <b>3,732.83</b> | <b>3,531.26</b> | <b>14,594.26</b> |
| 2      | <b>EXPENSES</b>   |                 |                 |                 |                  |
|        | Cost of Materials Consumed  | 1,891.56        | 1,728.01        | 1,784.39        | 7,080.54         |
|        | Changes in Inventories of Finished Goods, Stock-in-Trade and Work-in-Progress | (434.96)        | 8.85            | (60.73)         | (93.21)          |
|        | Employee Benefit Expenses   | 541.77          | 522.08          | 379.95          | 1,820.90         |
|        | Finance Costs   | 28.56           | 25.71           | 17.59           | 74.59            |
|        | Depreciation and Amortization Expenses  | 79.60           | 71.08           | 60.45           | 260.03           |
|        | Other Expenses  | 687.63          | 741.48          | 589.37          | 2,639.80         |
|        | <b>Total Expenses</b>   | <b>2,794.16</b> | <b>3,097.21</b> | <b>2,771.02</b> | <b>11,782.65</b> |
| 3      | <b>Profit/(loss) before exceptional items and tax (1-2)</b>                   | <b>708.77</b>   | <b>635.62</b>   | <b>760.24</b>   | <b>2,811.61</b>  |
| 4      | <b>Exceptional Items</b>  |                 |                 |                 |                  |
| 5      | <b>Profit/ (loss) before tax (3+4)</b>  | <b>708.77</b>   | <b>635.62</b>   | <b>760.24</b>   | <b>2,811.61</b>  |
| 6      | <b>Tax expense:</b>   |                 |                 |                 |                  |
|        | (I) Current Tax   | 167.40          | 177.93          | 181.86          | 721.44           |
|        | (II) Earlier year taxes   | 0.74            | (1.21)          | -               | (3.43)           |
|        | (III) Deferred Tax  | (0.31)          | (5.46)          | 0.65            | (8.89)           |
|        | <b>Total Tax (I+II)</b>   | <b>167.83</b>   | <b>171.26</b>   | <b>182.51</b>   | <b>709.12</b>    |
| 7      | <b>Profit (Loss) for the period after Tax (5-6)</b>                           | <b>540.94</b>   | <b>464.36</b>   | <b>577.73</b>   | <b>2,102.49</b>  |
| 8      | <b>Share in Profit of Associate</b>   | <b>75.12</b>    | <b>30.76</b>    | <b>172.72</b>   | <b>381.93</b>    |
| 9      | <b>Profit (Loss) for the period (7+8)</b>                                     | <b>616.06</b>   | <b>495.12</b>   | <b>750.45</b>   | <b>2,484.42</b>  |
| 10     | <b>Other comprehensive income (Net of Tax)</b>                                |                 |                 |                 |                  |
|        | Items that will not be reclassified to profit or loss                         | -               | -               | -               | -                |
| A      | Re-measurement gain on defined benefit plans                                  | 1.55            | 6.22            | -               | 6.22             |
|        | (i) Items that will be reclassified to profit or loss                         | -               | -               | -               | -                |
| B      | (ii) Income tax relating to items that will be reclassified to profit or loss | -               | -               | -               | -                |
|        | <b>Total Other Comprehensive Income for the period (A+B)(net of taxes)</b>    | <b>1.55</b>     | <b>6.22</b>     | <b>-</b>        | <b>6.22</b>      |
| 11     | <b>Total Comprehensive Income for the period (7+8)</b>                        | <b>617.61</b>   | <b>501.34</b>   | <b>750.45</b>   | <b>2,490.64</b>  |
| 12     | <b>Net profit attributable to:</b>  |                 |                 |                 |                  |
|        | Owners of the holding company   |                 |                 |                 |                  |
|        | Non-controlling interest  |                 |                 |                 |                  |
| 13     | <b>Other comprehensive income attributable to :</b>                           |                 |                 |                 |                  |
|        | Owners of the holding company   |                 |                 |                 |                  |
|        | Non-controlling interest  |                 |                 |                 |                  |
| 14     | <b>Total Comprehensive Income attributable to (10+11)</b>                     |                 |                 |                 |                  |
|        | Owners of the holding company   |                 |                 |                 |                  |
|        | Non-controlling interest  |                 |                 |                 |                  |
| 15     | <b>Paid-up equity share capital (Face Value of Rs. 10/- each)</b>             | <b>826.37</b>   | <b>826.37</b>   | <b>826.37</b>   | <b>826.37</b>    |
| 16     | <b>Other Equity</b>   |                 |                 |                 | <b>10,164.72</b> |
| 17     | <b>Earnings per equity share (face value of Rs.10/- each) not annualised</b>  |                 |                 |                 |                  |
|        | (1) Basic   | 7.47            | 6.07            | 9.08            | 30.06            |
|        | (2) Diluted   | 7.47            | 6.07            | 9.08            | 30.06            |

**Notes:**

- The above consolidated unaudited financial results for the quarter ended on 30.06.2023 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on August 10, 2023. The statutory auditors of the company have carried out a limited review of the aforesaid results. The results for the quarter ended June 30, 2023, are available on the BSE Limited website(www.bseindia.com) and on the company's Website(www.titanbiotechltd.com)
- The consolidated audited financial results for the quarter ended on 30.06.2023 include the results of following -  
Associate Company - Peptech Biosciences Limited
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law(Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter ended on 30th June, 2023 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- Previous period figures are regrouped/reclassified in line with the current period.
- The Company has only one reportable business segment.
- The consolidated audited financial results have been prepared in accordance with the Indian Accounting Standards ("Ind AS") specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India")
- Freight amount has been added in revenue from operation for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors  
for TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA  
Managing Director  
DIN-00027448



Place : Delhi  
Dated : 10.08.2023



**TITAN BIOTECH LIMITED**

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011-71239900, Email : hr@titanbiotechltd.com www.titanbiotechltd.com CIN : L74999RJ1992PLC013387

**STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2023**

(Rs. IN LAKHS) except for EPS


| S.NO. | PARTICULARS   | CONSOLIDATED  |            |            |            |
|-------|---|---------------|------------|------------|------------|
|       |   | QUARTER ENDED |            |            |            |
|       |   | 30.06.2023    | 31.03.2023 | 30.06.2022 | 31.03.2023 |
|       |   | UNAUDITED     | AUDITED    | UNAUDITED  | AUDITED    |
| 1     | Total Income from Operations (Net)  | 3,502.93      | 3,732.83   | 3,531.26   | 14,594.26  |
| 2     | Net Profit/(Loss) for the period (before tax, exceptional and/or extraordinary items)   | 708.77        | 635.62     | 760.24     | 2,811.61   |
| 3     | Net Profit/(Loss) for the period before tax (after exceptional and/or extraordinary items)  | 708.77        | 635.62     | 760.24     | 2,811.61   |
| 4     | Net Profit/(Loss) for the period after tax (after exceptional and/or extraordinary items)   | 616.06        | 495.12     | 750.45     | 2,484.42   |
| 5     | Total comprehensive income for the period (comprising Profit/(Loss) for the period(after tax) and Other Comprehensive income(after tax)(refer note 3) | 617.61        | 501.34     | 750.45     | 2,490.64   |
| 6     | Paid-up Equity Share Capital (Face value of Rs. 10/- per share)   | 826.37        | 826.37     | 826.37     | 826.37     |
| 7     | Other Equity excluding Revaluation Reserves as per the balance sheet  | -             | -          | -          | 10,164.72  |
| 8     | Earning Per Share (of INR 10/- each)  |               |            |            |            |
|       | (a) Basic   | 7.47          | 6.07       | 9.08       | 30.06      |
|       | (b) Diluted   | 7.47          | 6.07       | 9.08       | 30.06      |

**NOTES :**

- The above is an extract of the detailed format of consolidated unaudited Financial Results for the quarter ended on 30.06.2023 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the consolidated audited Financial Results for the said quarter ended on 30th June 2023 are available on the website of BSE Limited at [www.bseindia.com](http://www.bseindia.com) and on company website at [www.titanbiotechltd.com](http://www.titanbiotechltd.com).
- The above consolidated unaudited financial results for the quarter ended on 30.06.2023 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on August 10, 2023. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- The Company has elected to exercise the option permitted under section 115BAA of the Income Tax Act, 1961 as introduced by Taxation Law (Amendment) Ordinance 2019. Accordingly, the Company has recognized provision for income tax for the quarter ended on 30.06.2023 and remeasured its deferred tax balance on the basis of the rate prescribed in the said section.
- The consolidated unaudited financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS) specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
- Freight amount has been added in revenue from operation for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors  
for TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA  
Managing Director  
DIN-00027448



Place : Delhi  
Dated : 10.08.2023